Sutro Biopharma (STRO) Share-based Compensation (2017 - 2026)
Sutro Biopharma (STRO) posted Share-based Compensation of $1.7 million for Q4 2025, down 82.39% sequentially from $9.4 million in Q3 2025, and down 72.02% YoY from $5.9 million in Q4 2024.
Sutro Biopharma (STRO) Share-based Compensation (2017 - 2026) Analysis & Trends
Sutro Biopharma has reported Share-based Compensation for 9 years, with the latest figure at $1.7 million in Q4 2025.
- Quarterly Share-based Compensation fell 72.02% year-over-year to $1.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $19.4 million (up 2.03% YoY) and the FY2025 annual result came in at $14.0 million, down 43.26% from the prior year.
- Share-based Compensation eased to $1.7 million in Q4 2025 per STRO's latest filing, from $9.4 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $39.6 million in Q3 2022 and troughed at $374000.0 in Q1 2024.
- A 5-year average of $10.5 million and a median of $6.4 million in 2021 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2023 and 2025: Share-based Compensation slumped 98.22% in 2023, then jumped 1477.54% in 2025.
- Over 5 years, Share-based Compensation stood at $6.9 million in 2021, then jumped by 275.21% to $25.8 million in 2022, then plunged by 75.92% to $6.2 million in 2023, then fell by 4.95% to $5.9 million in 2024, then sank by 72.02% to $1.7 million in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $1.7 million, $9.4 million, and $5.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - | 2.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.01 Mn |
| Jun 30, 2026 | 2.01 Mn |
| Dec 31, 2025 | 1.66 Mn |
| Dec 31, 2025 | 1.66 Mn |
| Sep 30, 2025 | 9.40 Mn |
| Sep 30, 2025 | 9.40 Mn |
| Jun 30, 2025 | 5.26 Mn |
| Jun 30, 2025 | 5.26 Mn |
| Mar 31, 2025 | 5.90 Mn |
| Mar 31, 2025 | 5.90 Mn |
| Dec 31, 2024 | 5.92 Mn |
| Dec 31, 2024 | 5.92 Mn |
| Sep 30, 2024 | 6.55 Mn |
| Sep 30, 2024 | 6.55 Mn |
| Jun 30, 2024 | 6.16 Mn |
| Jun 30, 2024 | 6.16 Mn |
| Mar 31, 2024 | 374,000.00 |
| Mar 31, 2024 | 374,000.00 |
| Dec 31, 2023 | 6.22 Mn |
| Dec 31, 2023 | 6.22 Mn |